ReviewFrontiers in immunology2021
Less Severe Cases of COVID-19 in Sub-Saharan Africa: Could Co-infection or a Recent History of
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- COVID-19 and malaria co-infection: a systematic review of clinical outcomes in endemic areas.PeerJ · 2024Pooled it
- Seroprevalence of anti-SARS-CoV-2 and anti-Plasmodium falciparum and vivax antibodies in urban and rural zones in the West Region of Cameroon.BMC infectious diseases · 2025Article
- Explaining international differences in excess mortality due to Covid-19.Scientific reports · 2025Article
- Cellular immune response to SARS-CoV-2 and clinical presentation in individuals exposed to endemic malaria.Cell reports · 2024Article
- Article
- Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022.JAMA network open · 2023Article
- Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.Wellcome open research · 2023Article
- Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021.BMC infectious diseases · 2022Article
- Probing SARS-CoV-2-positive plasma to identify potential factors correlating with mild COVID-19 in Ghana, West Africa.BMC medicine · 2022Article
- Impact of COVID-19 and malaria coinfection on clinical outcomes: a retrospective cohort study.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Article
- High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers.BMC infectious diseases · 2022Article
- CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target.The Science of the total environment · 2022Review
- SARS-CoV-2 andFrontiers in public health · 2022Article
- High Seroprevalence of Anti-SARS-CoV-2 Antibodies Among Ethiopian Healthcare Workers.Research square · 2021Article
- COVID-19 Antibody Detecting Rapid Diagnostic Tests Show High Cross-Reactivity When Challenged with Pre-Pandemic Malaria, Schistosomiasis and Dengue Samples.Diagnostics (Basel, Switzerland) · 2021Article
- COVID-19: The African enigma.Colombia medica (Cali, Colombia) · 2021Article
- Cellular Therapy: The Hope for Covid-19.Avicenna journal of medical biotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Sub-Saharan Africa has generally experienced few cases and deaths of coronavirus disease 2019 (COVID-19). In addition to other potential explanations for the few cases and deaths of COVID-19 such as the population socio-demographics, early lockdown measures and the possibility of under reporting, we hypothesize in this mini review that individuals with a recent history of malaria infection may be protected against infection or severe form of COVID-19. Given that both the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.